Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment
Open Access
- 23 March 2016
- journal article
- other
- Published by Taylor & Francis in Cell Cycle
- Vol. 15 (9) , 1295-1302
Abstract
Triple-negative breast cancer (TNBC) represents an aggressive cancer subtype characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). The independence of TNBC from these growth promoting factors eliminates the efficacy of therapies which specifically target them, and limits TNBC patients to traditional systemic neo/adjuvant chemotherapy. To better understand the growth advantage of TNBC – in the absence of ER, PR and HER2, we focused on the embryonic morphogen Nodal (associated with the cancer stem cell phenotype), which is re-expressed in aggressive breast cancers. Most notably, our previous data demonstrated that inhibition of Nodal signaling in breast cancer cells reduces their tumorigenic capacity. Furthermore, inhibiting Nodal in other cancers has resulted in improved effects of chemotherapy, although the mechanisms for this remain unknown. Thus, we hypothesized that targeting Nodal in TNBC cells in combination with conventional chemotherapy may improve efficacy and represent a potential new strategy. Our preliminary data demonstrate that Nodal is highly expressed in TNBC when compared to invasive hormone receptor positive samples. Treatment of Nodal expressing TNBC cell lines with a neutralizing anti-Nodal antibody reduces the viability of cells that had previously survived treatment with the anthracycline doxorubicin. We show that inhibiting Nodal may alter response mechanisms employed by cancer cells undergoing DNA damage. These data suggest that development of therapies which target Nodal in TNBC may lead to additional treatment options in conjunction with chemotherapy regimens – by altering signaling pathways critical to cellular survival.Keywords
This publication has 40 references indexed in Scilit:
- Activin/Nodal signalling in stem cellsDevelopment, 2015
- Triple-negative breast cancer: new perspectives for novel therapiesMedical Oncology, 2013
- Neoadjuvant treatments for triple-negative breast cancer (TNBC)Annals of Oncology, 2012
- Nodal/Activin Signaling Drives Self-Renewal and Tumorigenicity of Pancreatic Cancer Stem Cells and Provides a Target for Combined Drug TherapyCell Stem Cell, 2011
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Triple-Negative Breast CancerThe Cancer Journal, 2010
- Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell linesBreast Cancer Research and Treatment, 2009
- Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical interventionExpert Review of Dermatology, 2009
- Understanding and treating triple-negative breast cancer.2008
- Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancerCancer Chemotherapy and Pharmacology, 1986